ACHIEVE GREATER OUTCOMES FOR YOUR PATIENTS

SARCLISA SARCLISA

Superior PFS with SARCLISA + Pd vs Pd alone1

See the Full Efficacy Data

75-minute infusion time after the second infusion (in the absence of IRRs)1

View Dosing

Resources to help eligible patients access SARCLISA

Learn About CareASSIST

*ORR included sCR, CR, VGPR, and PR. sCR, CR, VGPR, and PR were evaluated by an IRC using the IMWG response criteria. CR=complete response; IMWG=International Myeloma Working Group; IRC=independent response committee; IRR=infusion-related reaction; ORR=overall response rate; PFS=progression-free survival; PR=partial response; sCR=stringent complete response; VGPR=very good partial response.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Category 1, Preferred recommendation for isatuximab-irfc (SARCLISA)

Isatuximab-irfc (SARCLISA), in combination with pomalidomide and dexamethasone, is a Category 1, Preferred option for previously treated multiple myeloma by the National Comprehensive Cancer Network® (NCCN®).2

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

References: 1. SARCLISA [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.5.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed March 30, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org.